Sanofi Pasteur reports high immune response of H5N1 vaccine

Pharmaceutical Company Product News

Sanofi Pasteur has announced data showing that its investigational H5N1 pandemic influenza vaccine - which contains a proprietary adjuvant - has shown a high immune response, while being administered at the lowest reported rate of such an antigen.

The company reports that 70 per cent of the clinical trial participants exhibited a high level seroprotective immune response when receiving the vaccine containing 1.9 micrograms of antigen.

Administration of a vaccine containing 3.75 micrograms of antigen resulted in a high level response rate of 80 per cent of participants in the study.

"Once fully developed, this vaccine should give Sanofi Pasteur the potential to provide billions of doses in a pandemic situation and greatly increases its ability to produce vaccines for stockpiling in advance of a pandemic," the company reports

It adds that such stockpiling would mark a key public health achievement and a research and development breakthrough for the development of pandemic and pre-pandemic vaccines, in line with the firm's dedication to meeting the challenge presented by the disease.

In July 2007, Sanofi Pasteur announced the completion of construction work at its new $150 million (73 million pound) influenza manufacturing site, with the facility due to come online in late 2008 or early 2009 following regulatory approval.

See all the latest jobs in Pharmaceutical
Return to news